{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-26-000028","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.205236+00:00","generated_at":"2026-05-15T07:49:17.355600+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated","bullets":["Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.","Resignation not due to any disagreement with company's operations, policies, or practices.","Company has initiated a search for Daniels' successor; CEO thanked Daniels for his contributions.","Kiora continues enrollment in KIO-301 (ABACUS-2) and KIO-104 (KLARITY) Phase 2 trials.","Safety reviews cleared for KIO-301 50µg and 100µg dose cohorts; KIO-104 enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-26-000028","json":"https://secwatch.observer/filing/0001372514-26-000028.json","markdown":"https://secwatch.observer/filing/0001372514-26-000028.md","text":"https://secwatch.observer/filing/0001372514-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000028/0001372514-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000028/kprx-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:49:17.355600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}